β-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy

Cancer Research

Volumn 70, Issue 10, 2010, Pages 3896-3904

  Blanco, Elvin ^a   Bey, Erik A ^a   Khemtong, Chalermchai ^a   Yang, Su Geun ^a   Setti Guthi, Jagadeesh ^a   Chen, Huabing ^a   Kessinger, Chase W ^a   Carnevale, Kevin A ^b   Bornmann, William G ^c   Boothman, David A ^a   Gao, Jinming ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA LAPACHONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG STABILITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LUNG SMALL CELL CANCER; MICELLE; MICELLIZATION; MOUSE; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICELLES; NAD(P)H DEHYDROGENASE (QUINONE); NANOMEDICINE; NAPHTHOQUINONES; SURVIVAL RATE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952866189     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3995     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249
2. Belinsky M, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993;12:103-117 (Pubitemid 23220675)
3. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:quinone oxidoreductase activity is the principal determinant of β-lapachone cytotoxicity. J Biol Chem 2000;275:5416-5424 (Pubitemid 30115173)
4. Bey EA, Bentle MS, Reinicke KE, et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone. Proc Natl Acad Sci U S A 2007;104:11832-11837
5. Bentle MS, Bey EA, Dong Y, Reinicke KE, Boothman DA. New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. J Mol Histol 2006;37:203-218 (Pubitemid 44795624)
6. Bentle MS, Reinicke KE, Dong Y, Bey EA, Boothman DA. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, β-lapachone. Cancer Res 2007;67:6936-6945
7. Dong Y, Chin SF, Blanco E, et al. Intratumoral delivery of β-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res 2009;15:131-139
8. Nasongkla N, Wiedmann AF, Bruening A, et al. Enhancement of solubility and bioavailability of β-lapachone using cyclodextrin inclusion complexes. Pharm Res 2003;20:1626-1633 (Pubitemid 37268279)
9. Hartner L, Rosen L, Hensley M, et al. Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS). J Clin Oncol 2007;25:20521.
10. Kawecki A, Adkins DR, Cunningham CC, et al. A phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2007;25:16509.
11. Khong HT, Dreisbach L, Kindler HL, et al. A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:15017.
12. Li C, Nemunaitis J, Senzer N, et al. A phase Ib trial of ARQ 501, a selective checkpoint activator, in combination with docetaxel in patients with advanced solid tumors. J Clin Oncol 2006;24:13053.
13. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-760 (Pubitemid 350223348)
14. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-171
15. Gabizon AA. Pegylated liposomal doxorubicin:metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424-436
16. Lee CC, MacKay JA, Frechet JM, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol 2005;23:1517-1526
17. Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) 2009; 234:123-131
18. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007;24:1029-1046 (Pubitemid 46798882)
19. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001;73:137-172 (Pubitemid 32544594)
20. Haag R. Supramolecular drug-delivery systems based on polymeric core-shell architectures. Angew Chem Int Edit 2004;43:278-282 (Pubitemid 38090059)
21. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-1380 (Pubitemid 30660013)
22. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207. (Pubitemid 32520323)
23. Planchon SM, Wuerzberger S, Frydman B, et al. β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res 1995;55:3706-3711
24. Shuai X, Ai H, Nasongkla N, Kim S, Gao J. Micellar carriers based on block copolymers of poly(ε-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J Control Release 2004;98:415-426 (Pubitemid 39093952)
25. Blanco E, Bey EA, Dong Y, et al. β-Lapachone-containing PEGPLA polymer micelles as novel nanotherapeutics against NQO1- overexpressing tumor cells. J Control Release 2007;122:365-374 (Pubitemid 47404665)
26. Khemtong C, Kessinger CW, Ren J, et al. In vivo off-resonance saturation magnetic resonance imaging of αvβ3-targeted superparamagnetic nanoparticles. Cancer Res 2009;69:1651-1658
27. Kannan TR, Baseman JB. Hemolytic and hemoxidative activities in Mycoplasma penetrans. Infect Immun 2000;68:6419-6422
28. Lee J, El-Abaddi N, Duke A, Cerussi AE, Brenner M, Tromberg BJ. Noninvasive in vivo monitoring of methemoglobin formation and reduction with broadband diffuse optical spectroscopy. J Appl Physiol 2006;100:615-622 (Pubitemid 43671616)
29. Matsui M, Nakahara A, Takatsu A, Kato K, Matsuda N. In situ observation of reduction behavior of hemoglobin molecules adsorbed on glass surface. IEICE Trans Electron 2006;E89-C:1741-1745
30. Doki Y, Murakami K, Yamaura T, Sugiyama S, Misaki T, Saiki I. Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br J Cancer 1999;79:1121-1126 (Pubitemid 29087884)
31. Yang RY, Kizer D, Wu H, et al. Synthetic methods for the preparation of ARQ 501 (β-lapachone) human blood metabolites. Bioorg Med Chem 2008;16:5635-5643 (Pubitemid 351694469)
32. Liu J, Zeng F, Allen C. In vivo fate of unimers and micelles of a poly- (ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. Eur J Pharm Biopharm 2007;65:309-319
33. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J Control Release 2001; 77:27-38. (Pubitemid 33022613)
34. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8:610-622
35. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-284 (Pubitemid 30122932)
36. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 2003;300:615-618 (Pubitemid 36520581)
37. Michaelis M, Zimmer A, Handjou N, Cinatl J, Cinatl J, Jr. Increased systemic efficacy of aphidicolin encapsulated in liposomes. Oncol Rep 2005;13:157-160
38. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002;235:179-192
39. Radjendirane V, Joseph P, Lee YH, et al. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem 1998;273:7382-7389 (Pubitemid 28152759)
40. Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 1991;42:1021-1027